The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The development of a composite comorbidity index to predict CAR-T outcomes in patients with DLBCL
In this video, Geoffrey Shouse, DO, PhD, City of Hope, Duarte, CA, briefly discusses the development of a composite comorbidity index to predict outcomes of CAR-T therapy in patients with diffuse large B-cell lymphoma (DLBCL). This simplified cumulative illness rating scale (CIRS)-derived comorbidity index can be used as a tool to identify the patients at high risk of adverse outcomes following CAR-T. During the development of the index, the presence of a severe comorbidity in the respiratory, upper gastrointestinal, hepatic, or renal systems was found to have the most significant impact on survival. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
